Filtered By:
Condition: Bleeding
Drug: Amiodarone

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 42 results found since Jan 2013.

Can I use DOAC in a patient with renal disease?
Case A 76-year-old man is diagnosed with non-valvular atrial fibrillation. His comorbid conditions are hypertension, diabetes complicated by neuropathy, and chronic kidney disease stage 3. His current medications include metformin, lisinopril, gabapentin, and aspirin. His most recent laboratories showed a creatinine 1.8, creatinine clearance (CrCl) 35 mL/min, hemoglobin 11g/dL, and international normalized ratio 1.0. His congestive heart failure, hypertension, age, diabetes, stroke, vascular disease, and sex (CHADSVASc) score is 4. Which medication should we use to prevent stroke in this patient?  Brief overview of the is...
Source: The Hospitalist - February 3, 2022 Category: Hospital Management Authors: Ronda Whitaker Tags: Renal & Genitourinary Source Type: research

Role of new drugs for management of atrial fibrillation.
CONCLUSIONS: Use of dronedarone should be limited to patients with paroxysmal or persistent AF and should not be used in patients with heart failure or with permanent AF. Newer antithrombotic agents appear to be promising alternatives for the prevention of stroke in patients with AF; however, more data are needed to understand their role. PMID: 23249869 [PubMed - in process]
Source: The Annals of Pharmacotherapy - December 1, 2012 Category: Drugs & Pharmacology Authors: Hollands JM, Gowan M, Riney JN, Deal EN, Kates AM Tags: Ann Pharmacother Source Type: research

Outcomes in atrial fibrillation patients on combined warfarin & antiarrhythmic therapy
Conclusions: Allowing for differences in prescribing practice, AF/AFL patients treated with W+A are at higher risk of stroke and arterial embolism, and have higher healthcare use and costs, than patients receiving W+OAAD.
Source: International Journal of Cardiology - February 15, 2012 Category: Cardiology Authors: Annie Guérin, Jay Lin, Mehul Jhaveri, Eric Q. Wu, Andrew P. Yu, Martin Cloutier, Genevieve Gauthier, Joseph S. Alpert Tags: Original Articles Source Type: research

Association between Use of Pharmacokinetic-Interacting Drugs and Effectiveness and Safety of Direct Acting Oral Anticoagulants: Nested Case-Control Study
Clin Pharmacol Ther. 2021 Jul 19. doi: 10.1002/cpt.2369. Online ahead of print.ABSTRACTConcomitant use of direct oral anticoagulants (DOACs) and medications with inhibition/induction effect on P-gp/CYP3A might increase risk of bleeding/treatment failure, respectively. We designed a nested case-control study within a Clalit cohort of atrial fibrillation (AF) patients and a cohort of venous thromboembolic patients, new users of a DOAC (1.1.2010-24.8.2020). Propensity scores were constructed from demographic, clinical and medications at cohort entry. Each case of: 1) serious bleeding event; 2) stroke/systemic emboli (SE) in A...
Source: Clinical Pharmacology and Therapeutics - July 21, 2021 Category: Drugs & Pharmacology Authors: Naomi Gronich Nilli Stein Mordehcai Muszkat Source Type: research

Effects of Regional Differences in Asia on Efficacy and Safety of Edoxaban Compared With Warfarin　- Insights From the ENGAGE AF-TIMI 48 Trial.
CONCLUSIONS: HDE had a greater relative efficacy and safety in EA compared with Japan that was only partially explained by differences in baseline characteristics and TTR. PMID: 26460886 [PubMed - as supplied by publisher]
Source: Circulation Journal - October 9, 2015 Category: Cardiology Authors: Shimada YJ, Yamashita T, Koretsune Y, Kimura T, Abe K, Sasaki S, Mercuri M, Ruff CT, Giugliano RP Tags: Circ J Source Type: research

Non-vitamin K Antagonist Oral Anticoagulants (NOACs) Versus Warfarin in Patients with Atrial Fibrillation Using P-gp and/or CYP450-Interacting Drugs: a Systematic Review and Meta-analysis
ConclusionThe benefit-risk profile of NOACs compared to VKAs was preserved in AF patients using P-gp/CYP3A4 inhibitors, including amiodarone.
Source: Cardiovascular Drugs and Therapy - October 12, 2021 Category: Cardiology Source Type: research

Edoxaban vs. warfarin in patients with atrial fibrillation on amiodarone: a subgroup analysis of the ENGAGE AF-TIMI 48 trial
Conclusions Patients randomized to the LDE treated with amiodarone at the time of randomization demonstrated a significant reduction in ischaemic events vs. warfarin when compared with those not on amiodarone, while preserving a favourable bleeding profile. In contrast, amiodarone had no effect on the relative efficacy and safety of HDE.
Source: European Heart Journal - September 1, 2015 Category: Cardiology Authors: Steffel, J., Giugliano, R. P., Braunwald, E., Murphy, S. A., Atar, D., Heidbuchel, H., Camm, A. J., Antman, E. M., Ruff, C. T. Tags: Thrombosis and anti-thrombotic therapy Source Type: research

Cardiovascular Events of Electrical Cardioversion Under Optimal Anticoagulation in Atrial Fibrillation: The Multicenter Analysis.
CONCLUSION: Cardioversion appears as a safe procedure with a reasonably acceptable cardiovascular event rate. However, to prevent the cardiovascular events, several risk factors should be considered before cardioversion. PMID: 26446636 [PubMed - in process]
Source: Yonsei Medical Journal - October 9, 2015 Category: Universities & Medical Training Authors: Shin DG, Cho I, Hartaigh BÓ, Mun HS, Lee HY, Hwang ES, Park JK, Uhm JS, Pak HN, Lee MH, Joung B Tags: Yonsei Med J Source Type: research

Clinical outcomes in patients with atrial fibrillation receiving amiodarone on NOACs vs. warfarin
ConclusionAmong patients with AF taking amiodarone, there is no increased risk of stroke, major bleeding, or ICB with NOACs compared to warfarin.
Source: Journal of Interventional Cardiac Electrophysiology - August 20, 2018 Category: Cardiology Source Type: research

Factors Associated with Prolonged Survival in Left Ventricular Assist Device Recipients
ConclusionsPreoperative diabetes and amiodarone use were associated with poor long-term survival in LVAD recipients. Development of early complications of stroke, gastrointestinal bleeding, hemolysis, or pump thrombosis was also associated with poor long-term survival. Early diagnosis and treatment of these complications may improve survival in LVAD recipients.
Source: The Annals of Thoracic Surgery - October 12, 2018 Category: Cardiovascular & Thoracic Surgery Source Type: research

Factors Associated with Prolonged Survival in Left Ventricular Assist Device Recipients.
CONCLUSIONS: Preoperative diabetes and amiodarone use were associated with poor long-term survival in LVAD recipients. Development of early complications of stroke, gastrointestinal bleeding, hemolysis, or pump thrombosis was also associated with poor long-term survival. Early diagnosis and treatment of these complications may improve survival in LVAD recipients. PMID: 30316851 [PubMed - as supplied by publisher]
Source: The Annals of Thoracic Surgery - October 11, 2018 Category: Cardiovascular & Thoracic Surgery Authors: Xia Y, Forest S, Friedmann P, Chou LC, Patel S, Jorde U, Goldstein D Tags: Ann Thorac Surg Source Type: research